ARIUS Research Inc. company was founded in 1999 and is based in Toronto, Canada. As of September 23, 2008, Arius Research Inc. operates as a subsidiary of Roche Holding AG. ARIUS Research, Inc., a biotechnology company, engages in the discovery and development of antibody therapeutics primarily focusing on breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma. It identifies monoclonal antibodies targeting various cancer indications through its technology platform, FunctionFIRST. The company’s product pipeline includes CD63 program that is in preclinical studies for various cancer indications; ARH460-16-2, an antibody targeting the cancer stem cell antigen CD44; AR36A36.11.1 and AR10A304.7, which targets the complement-inhibitory molecule CD59; AR47A6.4.2 and AR52A301.5, which are monoclonal antibodies directed to the cancer-associated protein TROP-2 that is homologous to human EpCAM, an another cell surface cancer related protein; and AR40A746.2.3 that targets leukemia cancer stem cells. It also has antibody programs targeting the MCSP antigen and 37LRP. ARIUS has partnerships with Oxford BioMedica plc, Xerion Pharmaceuticals AG, PDL BioPharma, Inc., Medarex, Inc., Genentech, Inc., and Takeda Pharmaceutical Company Limited.

Marker Gene Technologies sells itself. The company offers drug researchers a variety of marker genes for monitoring gene expression, intracellular targeting, and other purposes. The company's marker genes are used in research for agricultural biotechnology, cell culturing, and bacteriology. Additional products include reagents, enzyme substrates and kits, and other molecular biology products. Marker Gene Technologies also maintains four fully equipped laboratories from which it provides contract research services for biotechnology and pharmaceutical clients. The firm markets its products through a number of distributors in the US and abroad, in Europe, Asia, and the Middle East.

Cancer is the only target of Onyvax. The development-stage biotech aims to come up with novel immunotherapies to treat advanced prostate and other forms of cancer. Onyvax's therapeutic cancer vaccines combine inactivated cell lines that create immune responses to tumor targets. The firm has several products in clinical trials, including lead candidate Onyvax-P, a cell vaccine that could treat hormone-resistant prostate cancer. While most of the company's candidates target specific types of cancer, its Onyvax-105 uses human monoclonal antibodies to attack the CD55 molecule, giving the therapy potential for treating many types of cancer.

Lipoxen Plc, a biopharmaceutical company, develops drug and vaccine delivery systems, and proprietary products in the fields of protein drugs, vaccines, and oncology. The company’s product candidates under development include ErepoXen for the treatment to maintain the red blood cell population and prevent anaemia; StimuXen for the treatment of neutropenia; InferoXen for hepatitis C; SuliXen for the treatment of type II diabetes; LipoNeu for streptococcus pneumoniae; LipoTet, an oral liposomal tetanus vaccine; HepaXen to prevent and treat hepatitis B; LipoRab, a rabies vaccine candidate; and LipoTaxen, an anti-cancer drug for the treatment of lung, breast, ovarian, and other cancers. It has operations in the United States, Europe, and India. Lipoxen Plc has a collaboration agreement with Pharmsynthez JSC. The company is based in London, the United Kingdom.

Biosite Incorporated company's diagnostic products include its Triage Drugs of Abuse Panel and Triage TOX Drug Screen which are used in hospital settings to test for commonly abused drugs. Its other diagnostic products include tests to detect intestinal parasites, diagnose congestive heart failure, and measure the biomarkers associated with stroke. The Biosite Discovery program is a collaborative research effort to identify protein markers for a variety of ailments. Medical diagnostics firm Inverness Medical Innovations acquired Biosite in 2007.

Biovail Corporation company was founded in 1983 and is headquartered in Mississauga, Canada. Biovail Corporation, a pharmaceutical company, engages in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products principally in the United States and Canada. The company focuses on central nervous system disorders, pain management, and cardiovascular diseases. Its products include Xenazine for the treatment of chorea associated with Huntington's disease; Wellbutrin XL for the treatment of depression in adults; Ultram ER for the management of chronic pain in adults; Zovirax Ointment for the management of initial genital herpes; Zovirax Cream for the treatment of herpes labialis; and Cardizem LA that provides blood pressure control.Biovail Corporation company also provides Tiazac/Tiazac XC for the treatment of hypertension and angina; Wellbutrin SR for the treatment of depression; Zyban for smoking cessation treatment; Monocor for the treatment of hypertension and congestive heart failure; Retavase, a tissue plasminogen activator used in thrombolytic therapy; Glumetza to control hyperglycemia in adult patients with non-insulin dependent and mature onset diabetes; Ralivia for the management of pain; and Nitoman for the treatment of hyperkinetic movement disorders, such as Huntington's chorea, Hemiballismus, Senile Chorea, Tic and Gilles de la Tourette Syndrome, and Tardive Dyskinesia. Its legacy products comprise Cardizem CD medications in the calcium channel blocker category of cardiovascular drugs; Ativan for the management of anxiety disorders; and Isordil to treat prophylaxis of ischemic heart pain associated with coronary insufficiency. The company's generic products consist of bioequivalent formulations of Cardizem CD, Adalat CC, Procardia XL, Tiazac, Voltaren XR, and Trental. In addition, it offers research, development, and clinical contract research services to third parties.

Nature's Way Holding Company manufactures and markets nutritional supplements and other OTC products which are sold with the Enzymatic Therapy, Nature's Way, and Remifemin labels through natural foods retailers and mass market retailers in the US. Its products are aimed to alleviate everything from sleeplessness to hot flashes and are distributed throughout the US and to more than 40 other countries. Its Integrative Therapeutics and Vitaline brands are sold through healthcare practitioners' offices. The company is a unit of German firm Dr. Willmar Schwabe Pharmaceuticals.

Blansett Pharmacal Co., Inc. company's products include respiratory drugs Prolex and Nalex, tension headache remedy Anolor, and swimmer's ear treatment Cortane. Blansett also makes medications for women's health and hemorrhoids. On top of developing its own products, the company markets under-promoted products developed by other pharmaceutical companies. Blansett Pharmacal was founded in 1982 in North Little Rock, Arkansas; its products are distributed throughout the US.

Aspreva Pharmaceuticals believes that bad aim can be a good thing when treating diseases. This company conducts clinical trials to find new uses for approved drugs. As a result, partners team up with Aspreva to gain incremental revenue from the commercialization of the new version of the drug. Working in collaboration with Roche, Aspreva conducts clinical trials to investigate the use of Roche's CellCept (indicated for prevention of rejection in organ transplant patients) to treat autoimmune diseases including lupus nephritis and pemphigus vulgaris. Aspreva is a subsidiary of Swiss pharmaceutical firm Galenica Group.

Orexigen Therapeutics was founded in 2002 and is headquartered in La Jolla, California. Orexigen Therapeutics, Inc., a biopharmaceutical company, focusing on the development of pharmaceutical product candidates for the treatment of obesity. Orexigen Therapeutics's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. It selected these two product candidates for obesity based research regarding CNS regulation of appetite and energy expenditure, as well as mechanisms in the brain that reinforce unhealthy eating behaviors. Each of these product candidates is a combination of generic drugs that is screened for synergistic CNS activity.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.